Heat Biologics, Inc. (HTBX): Price and Financial Metrics

Heat Biologics, Inc. (HTBX): $2.38

0.01 (+0.42%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add HTBX to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#184 of 395

in industry

HTBX Price/Volume Stats

Current price $2.38 52-week high $10.85
Prev. close $2.37 52-week low $2.07
Day low $2.33 Volume 43,600
Day high $2.48 Avg. volume 171,558
50-day MA $2.65 Dividend yield N/A
200-day MA $4.38 Market Cap 61.05M

HTBX Stock Price Chart Interactive Chart >


Heat Biologics, Inc. (HTBX) Company Bio


Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.


HTBX Latest News Stream


Event/Time News Detail
Loading, please wait...

HTBX Latest Social Stream


Loading social stream, please wait...

View Full HTBX Social Stream

HTBX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Continue Researching HTBX

Here are a few links from around the web to help you further your research on Heat Biologics Inc's stock as an investment opportunity:

Heat Biologics Inc (HTBX) Stock Price | Nasdaq
Heat Biologics Inc (HTBX) Stock Quote, History and News - Yahoo Finance
Heat Biologics Inc (HTBX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!